Skip to main content
Log in

Understanding the role of radiologists in complex treatment decisions for patients with hepatocellular carcinoma

  • Review
  • Published:
Abdominal Radiology Aims and scope Submit manuscript

Abstract

Hepatocellular carcinoma (HCC) is the most common primary malignant tumor of the liver and represents a significant global health burden. Management of HCC can be challenging due to multiple factors, including variable expectations for treatment outcomes. Several treatment options are available, each with specific eligibility and ineligibility criteria, and are provided by a multidisciplinary team of specialists. Radiologists should be aware of the types of treatment options available, as well as the criteria guiding the development of individualized treatment plans. This awareness enables radiologists to contribute effectively to patient-centered multidisciplinary tumor boards for HCC and play a central role in reassessing care plans when the treatment response is deemed inadequate. This comprehensive review aims to equip radiologists with an overview of HCC staging systems, treatment options, and eligibility criteria. The review also discusses the significance of imaging in HCC diagnosis, treatment planning, and monitoring treatment response. Furthermore, we highlight the crucial branch points in the treatment decision-making process that depend on radiological interpretation.

Graphical abstract

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Konyn, P., A. Ahmed, and D. Kim, Current epidemiology in hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol, 2021. 15(11): p. 1295-1307.

    Article  CAS  PubMed  Google Scholar 

  2. Kulik, L. and H.B. El-Serag, Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology, 2019. 156(2): p. 477-491 e1.

    Article  PubMed  Google Scholar 

  3. Ayuso, C., et al., Diagnosis and staging of hepatocellular carcinoma (HCC): current guidelines. Eur J Radiol, 2018. 101: p. 72-81.

    Article  PubMed  Google Scholar 

  4. Reig, M., et al., BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol, 2022. 76(3): p. 681-693.

    Article  PubMed  Google Scholar 

  5. Amorim, J., et al., Critical review of HCC imaging in the multidisciplinary setting: treatment allocation and evaluation of response. Abdom Radiol (NY), 2020. 45(10): p. 3119-3128.

    Article  CAS  PubMed  Google Scholar 

  6. Sinn, D.H., et al., Multidisciplinary approach is associated with improved survival of hepatocellular carcinoma patients. PLoS One, 2019. 14(1): p. e0210730.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Shenoy-Bhangle, A.S., et al., Role of the radiologist at HCC multidisciplinary conference and use of the LR-TR algorithm for improving workflow. Abdom Radiol (NY), 2021. 46(8): p. 3558-3564.

    Article  PubMed  Google Scholar 

  8. Amin, M.B., et al., The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin, 2017. 67(2): p. 93-99.

    Article  PubMed  Google Scholar 

  9. Wiesner, R., et al., Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology, 2003. 124(1): p. 91-6.

    Article  PubMed  Google Scholar 

  10. Galle, P.R., et al., Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. Liver Int, 2019. 39(12): p. 2214-2229.

    Article  PubMed  Google Scholar 

  11. Tangkijvanich, P., et al., Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. J Clin Gastroenterol, 2000. 31(4): p. 302-8.

    Article  CAS  PubMed  Google Scholar 

  12. Ikai, I., et al., Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer, 2004. 101(4): p. 796-802.

    Article  PubMed  Google Scholar 

  13. Mehta, N., et al., Validation of the prognostic power of the RETREAT score for hepatocellular carcinoma recurrence using the UNOS database. Am J Transplant, 2018. 18(5): p. 1206-1213.

    Article  CAS  PubMed  Google Scholar 

  14. Pusceddu, C., et al., The Increasing Role of CT-Guided Cryoablation for the Treatment of Liver Cancer: A Single-Center Report. Cancers (Basel), 2022. 14(12).

    Article  CAS  PubMed  Google Scholar 

  15. Han, J., Y.C. Fan, and K. Wang, Radiofrequency ablation versus microwave ablation for early stage hepatocellular carcinoma: A PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore), 2020. 99(43): p. e22703.

    Article  PubMed  Google Scholar 

  16. Musick, J.R., et al., Laparoscopic microwave ablation versus percutaneous microwave ablation of hepatic malignancies: Efficacy and recurrence-free survival outcomes in patients. Surgery, 2023. 173(3): p. 598-602.

    Article  PubMed  Google Scholar 

  17. Cucchetti, A., et al., Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma. J Hepatol, 2013. 59(2): p. 300-7.

    Article  PubMed  Google Scholar 

  18. Cho, Y.K., et al., Hepatic resection versus radiofrequency ablation for very early stage hepatocellular carcinoma: a Markov model analysis. Hepatology, 2010. 51(4): p. 1284-90.

    Article  PubMed  Google Scholar 

  19. Fuks, D., et al., Benefit of initial resection of hepatocellular carcinoma followed by transplantation in case of recurrence: an intention-to-treat analysis. Hepatology, 2012. 55(1): p. 132-40.

    Article  PubMed  Google Scholar 

  20. Berzigotti, A., et al., Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis. Hepatology, 2015. 61(2): p. 526-36.

    Article  PubMed  Google Scholar 

  21. Ferrer-Fabrega, J., et al., Prospective validation of ab initio liver transplantation in hepatocellular carcinoma upon detection of risk factors for recurrence after resection. Hepatology, 2016. 63(3): p. 839-49.

    Article  PubMed  Google Scholar 

  22. Mazzaferro, V., et al., Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med, 1996. 334(11): p. 693-9.

    Article  CAS  PubMed  Google Scholar 

  23. Machicao, V.I., Model for End-Stage Liver Disease-Sodium Score: The Evolution in the Prioritization of Liver Transplantation. Clin Liver Dis, 2017. 21(2): p. 275-287.

    Article  PubMed  Google Scholar 

  24. Kloeckner, R., P.R. Galle, and J. Bruix, Local and Regional Therapies for Hepatocellular Carcinoma. Hepatology, 2021. 73 Suppl 1: p. 137-149.

    Article  PubMed  Google Scholar 

  25. Couri, T. and A. Pillai, Goals and targets for personalized therapy for HCC. Hepatol Int, 2019. 13(2): p. 125-137.

    Article  PubMed  Google Scholar 

  26. Guiu, B., et al., TARE in Hepatocellular Carcinoma: From the Right to the Left of BCLC. Cardiovasc Intervent Radiol, 2022. 45(11): p. 1599-1607.

    Article  PubMed  Google Scholar 

  27. Lewandowski, R.J., et al., A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant, 2009. 9(8): p. 1920-8.

    Article  CAS  PubMed  Google Scholar 

  28. Gabr, A., et al., Liver Transplantation Following Yttrium-90 Radioembolization: 15-Year Experience in 207-Patient Cohort. Hepatology, 2021. 73(3): p. 998-1010.

    Article  CAS  PubMed  Google Scholar 

  29. Salem, R., et al., Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma. Gastroenterology, 2016. 151(6): p. 1155-1163 e2.

    Article  PubMed  Google Scholar 

  30. Gabr, A., et al., Correlation of Y90-absorbed radiation dose to pathological necrosis in hepatocellular carcinoma: confirmatory multicenter analysis in 45 explants. Eur J Nucl Med Mol Imaging, 2021. 48(2): p. 580-583.

    Article  CAS  PubMed  Google Scholar 

  31. Riaz, A., R. Awais, and R. Salem, Side effects of yttrium-90 radioembolization. Front Oncol, 2014. 4: p. 198.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Shampain, K.L., et al., SBRT for HCC: Overview of technique and treatment response assessment. Abdom Radiol (NY), 2021. 46(8): p. 3615-3624.

    Article  PubMed  Google Scholar 

  33. Lasley, F.D., et al., Treatment variables related to liver toxicity in patients with hepatocellular carcinoma, Child-Pugh class A and B enrolled in a phase 1-2 trial of stereotactic body radiation therapy. Pract Radiat Oncol, 2015. 5(5): p. e443-e449.

    Article  PubMed  Google Scholar 

  34. Benson, A.B., et al., Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 2021. 19(5): p. 541-565.

    Article  PubMed  Google Scholar 

  35. Cannon, R., et al., Safety and early efficacy of irreversible electroporation for hepatic tumors in proximity to vital structures. J Surg Oncol, 2013. 107(5): p. 544-9.

    Article  PubMed  Google Scholar 

  36. Lu, D.S., et al., Radiofrequency ablation of hepatocellular carcinoma: treatment success as defined by histologic examination of the explanted liver. Radiology, 2005. 234(3): p. 954-60.

    Article  PubMed  Google Scholar 

  37. Bhutiani, N., et al., Evaluation of tolerability and efficacy of irreversible electroporation (IRE) in treatment of Child-Pugh B (7/8) hepatocellular carcinoma (HCC). HPB (Oxford), 2016. 18(7): p. 593-9.

    Article  PubMed  Google Scholar 

  38. Zou, Y.W., et al., The latest research progress on minimally invasive treatments for hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int, 2023. 22(1): p. 54-63.

    Article  PubMed  Google Scholar 

  39. Harris, P.S., et al., Hepatocellular carcinoma surveillance: An evidence-based approach. World J Gastroenterol, 2019. 25(13): p. 1550-1559.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Chernyak, V., et al., Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients. Radiology, 2018. 289(3): p. 816-830.

    Article  PubMed  Google Scholar 

  41. Eisenbrey, J.R., et al., Contrast-enhanced ultrasound (CEUS) in HCC diagnosis and assessment of tumor response to locoregional therapies. Abdom Radiol (NY), 2021. 46(8): p. 3579-3595.

    Article  PubMed  Google Scholar 

  42. Bartolotta, T.V., et al., Contrast-enhanced ultrasound of hepatocellular carcinoma: where do we stand? Ultrasonography, 2019. 38(3): p. 200-214.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Kambadakone, A.R., et al., LI-RADS technical requirements for CT, MRI, and contrast-enhanced ultrasound. Abdom Radiol (NY), 2018. 43(1): p. 56-74.

    Article  PubMed  Google Scholar 

  44. Di Tommaso, L., et al., Role of liver biopsy in hepatocellular carcinoma. World J Gastroenterol, 2019. 25(40): p. 6041-6052.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Toniutto, P., et al., Liver Transplantation in Patients with Hepatocellular Carcinoma beyond the Milan Criteria: A Comprehensive Review. J Clin Med, 2021. 10(17).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Seuss, C.R., et al., Comparison of MRI pulse sequences for prediction of size of hepatocellular carcinoma at explant evaluation. AJR Am J Roentgenol, 2014. 203(2): p. 300-5.

    Article  PubMed  Google Scholar 

  47. Dietrich, O., et al., Technical aspects of MR diffusion imaging of the body. European Journal of Radiology, 2010. 76(3): p. 314-322.

    Article  PubMed  Google Scholar 

  48. Jha, R.C., S.S. Khera, and A.D. Kalaria, Portal Vein Thrombosis: Imaging the Spectrum of Disease With an Emphasis on MRI Features. AJR Am J Roentgenol, 2018. 211(1): p. 14-24.

    Article  PubMed  Google Scholar 

  49. Sherman, C.B., et al., Distinguishing Tumor From Bland Portal Vein Thrombus in Liver Transplant Candidates With Hepatocellular Carcinoma: the A-VENA Criteria. Liver Transpl, 2019. 25(2): p. 207-216.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Kawagishi, N., HCC with portal vein tumor thrombosis: how to manage? Hepatol Int, 2020. 14(5): p. 609-611.

    Article  PubMed  Google Scholar 

  51. Hatano, E., et al., Significance of hepatic resection and adjuvant hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombus in the first branch of portal vein and the main portal trunk: a project study for hepatic surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci, 2018. 25(9): p. 395-402.

    Article  PubMed  Google Scholar 

  52. Kokudo, T., et al., Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion. J Hepatol, 2016. 65(5): p. 938-943.

    Article  PubMed  Google Scholar 

  53. Lau, W.Y., et al., Treatment for hepatocellular carcinoma with portal vein tumor thrombosis: the emerging role for radioembolization using yttrium-90. Oncology, 2013. 84(5): p. 311-8.

    Article  CAS  PubMed  Google Scholar 

  54. Xu, Y.C., F. Yang, and D.L. Fu, Clinical significance of variant hepatic artery in pancreatic resection: A comprehensive review. World J Gastroenterol, 2022. 28(19): p. 2057-2075.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Entezari, P., et al., Promoting Surgical Resection through Future Liver Remnant Hypertrophy. Radiographics, 2022. 42(7): p. 2166-2183.

    Article  PubMed  Google Scholar 

  56. Lian, D., et al., CT volumetry helps predict prognosis of large hepatocellular carcinoma after resection. Clin Radiol, 2022. 77(8): p. e599-e605.

    Article  CAS  PubMed  Google Scholar 

  57. Lim, M.C., et al., CT volumetry of the liver: where does it stand in clinical practice? Clin Radiol, 2014. 69(9): p. 887-95.

    Article  CAS  PubMed  Google Scholar 

  58. Forner, A., J.M. Llovet, and J. Bruix, Hepatocellular carcinoma. Lancet, 2012. 379(9822): p. 1245-55.

    Article  PubMed  Google Scholar 

  59. Uka, K., et al., Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma. World J Gastroenterol, 2007. 13(3): p. 414-20.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Kielar, A., et al., Locoregional therapies for hepatocellular carcinoma and the new LI-RADS treatment response algorithm. Abdom Radiol (NY), 2018. 43(1): p. 218-230.

    Article  PubMed  Google Scholar 

  61. Ram, R., et al., LI-RADS treatment response lexicon: review, refresh and resolve with emerging data. Abdom Radiol (NY), 2021. 46(8): p. 3549-3557.

    Article  PubMed  Google Scholar 

  62. Aslam, A., et al., Hepatocellular carcinoma Liver Imaging Reporting and Data Systems treatment response assessment: Lessons learned and future directions. World J Hepatol, 2020. 12(10): p. 738-753.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Mendiratta-Lala, M., et al., Natural history of hepatocellular carcinoma after stereotactic body radiation therapy. Abdom Radiol (NY), 2020. 45(11): p. 3698-3708.

    Article  PubMed  Google Scholar 

  64. Llovet, J.M. and R. Lencioni, mRECIST for HCC: Performance and novel refinements. J Hepatol, 2020. 72(2): p. 288-306.

    Article  PubMed  Google Scholar 

  65. Ronot, M., et al., Imaging to Predict Prognosis in Hepatocellular Carcinoma: Current and Future Perspectives. Radiology, 2023. 307(3): p. e221429.

    Article  PubMed  Google Scholar 

  66. Li, X., et al., Correlations between the minimum and mean apparent diffusion coefficient values of hepatocellular carcinoma and tumor grade. J Magn Reson Imaging, 2016. 44(6): p. 1442-1447.

    Article  PubMed  Google Scholar 

  67. Witjes, C.D., et al., Histological differentiation grade and microvascular invasion of hepatocellular carcinoma predicted by dynamic contrast-enhanced MRI. J Magn Reson Imaging, 2012. 36(3): p. 641-7.

    Article  PubMed  Google Scholar 

  68. Ocal, O., et al., Prognostic value of baseline imaging and clinical features in patients with advanced hepatocellular carcinoma. Br J Cancer, 2022. 126(2): p. 211-218.

    Article  PubMed  Google Scholar 

  69. Wang, W., et al., The clinical significance of microvascular invasion in the surgical planning and postoperative sequential treatment in hepatocellular carcinoma. Sci Rep, 2021. 11(1): p. 2415.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Chong, H.H., et al., Multi-scale and multi-parametric radiomics of gadoxetate disodium-enhanced MRI predicts microvascular invasion and outcome in patients with solitary hepatocellular carcinoma </= 5 cm. Eur Radiol, 2021. 31(7): p. 4824-4838.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Calderaro, J., et al., Molecular and histological correlations in liver cancer. J Hepatol, 2019. 71(3): p. 616-630.

    Article  CAS  PubMed  Google Scholar 

  72. Kim, G.H., et al., Emerging Trends in the Treatment of Advanced Hepatocellular Carcinoma: A Radiological Perspective. Korean J Radiol, 2021. 22(11): p. 1822-1833.

    Article  PubMed  PubMed Central  Google Scholar 

  73. Llovet, J.M., et al., Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol, 2021. 18(5): p. 293-313.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Omar Kamal.

Ethics declarations

Conflict of interest

The author have no conflict of interest to declare.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kamal, O., Horvat, N., Arora, S. et al. Understanding the role of radiologists in complex treatment decisions for patients with hepatocellular carcinoma. Abdom Radiol 48, 3677–3687 (2023). https://doi.org/10.1007/s00261-023-04033-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00261-023-04033-6

Keywords

Navigation